Cell Biotech Co., Ltd. (KOSDAQ:049960)

Market Cap	111.76B +28.8%
Revenue (ttm)	56.49B +17.4%
Net Income	13.41B -3.8%
EPS	1,959.71 -3.7%
Shares Out	6.84M
PE Ratio	8.33
Forward PE	n/a
Dividend	600.00 (3.67%)
Ex-Dividend Date	Dec 29, 2025

Volume	21,542
Open	16,760
Previous Close	16,900
Day's Range	16,030 - 16,760
52-Week Range	11,350 - 18,500
Beta	0.44
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Dialog Axiata

Cell Biotech Co., Ltd., a biotechnology company, develops lactic acid bacteria products in South Korea and internationally. It engages in the probiotics, microbiome, and anticancer new drug businesses. The company sells its products through partnerships with multinational companies and local retailers under the DUOLAC, DUOLAB, LACTOClear, and LAB2PRO brand names. Cell Biotech Co., Ltd. was founded in 1995 and is based in Gimpo-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1995
• Employees: 101
• Stock Exchange: KOSDAQ
• Ticker Symbol: 049960

Financial Performance

In 2025, Cell Biotech's revenue was 53.13 billion, an increase of 6.44% compared to the previous year's 49.91 billion. Earnings were 10.13 billion, a decrease of -33.06%.